年龄与治疗类别改变老年多发性硬化患者停用疾病修饰治疗后的炎症风险
该研究为倾向评分匹配的前瞻性队列,纳入≥50岁多发性硬化患者,分析停用疾病修饰治疗(DMT)后炎症结局随年龄与治疗机制的变化。结果显示,>60岁者及停用抗CD20治疗者风险衰减,年龄与治疗机制可能有助于个体化风险分层。
要点
- ≥50岁多发性硬化患者停用DMT后仍可出现炎症再激活。
- >60岁患者及停用抗CD20治疗者,停药后炎症风险衰减。
- 年龄与治疗机制可能有助于停用DMT时的个体化风险分层。
核心结论
- 在≥50岁多发性硬化患者中,停用DMT后炎症结局随年龄和治疗机制而异,>60岁者及停用抗CD20治疗者风险衰减。
研究设计与样本
- 倾向评分匹配的前瞻性队列研究,纳入年龄≥50岁的多发性硬化患者。
主要发现
- 停用DMT后炎症结局随年龄和治疗机制变化,>60岁个体及停用抗CD20治疗者风险衰减。
临床怎么用
- 年龄和治疗机制可能有助于在考虑老年多发性硬化患者停用DMT时进行个体化风险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Discontinuation of disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be followed by inflammatory reactivation, even in older patients, but the age threshold at which this risk becomes substantially attenuated remains unclear. WHAT THIS STUDY ADDS In this propensity score-matched, prospective cohort of people with MS aged ≥50 years, inflammatory outcomes after DMT discontinuation vary by age and treatment mechanism, with attenuation of risk in individuals aged >60 years and among those discontinuing anti-CD20 therapies. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Age and treatment mechanism may help inform individualised risk stratification when considering DMT discontinuation in older people with MS. Introduction The proportion of older people with multiple sclerosis (MS) is steadily increasing, 1 likely due to better prognosis, 2 advances in disease-modifying therapies (DMTs) and expanded access...
引用
- Journal of Neurology, Neurosurgery and Psychiatry:Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。